Sen. John Boozman Sells IQVIA Holdings Inc. (NYSE:IQV) Shares

Senator John Boozman (R-Arkansas) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on November 15th, the Senator disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on October 2nd.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Tortoise North American Pipeline Fund (NYSEARCA:TPYP) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of Omnicom Group (NYSE:OMC) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 10/9/2025.
• Sold $1,001 – $15,000 in shares of Sprott Lithium Miners ETF (NASDAQ:LITP) on 10/3/2025.
• Sold $1,001 – $15,000 in shares of iShares Silver Trust (NYSEARCA:SLV) on 10/3/2025.
• Sold $15,001 – $50,000 in shares of First Trust North American Energy Infrastructure Fund (NYSEARCA:EMLP) on 10/3/2025.
• Purchased $15,001 – $50,000 in shares of FT Energy Income Partners Enhanced Income ETF (NYSEARCA:EIPI) on 10/3/2025.
• Purchased $1,001 – $15,000 in shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on 10/3/2025.
• Sold $1,001 – $15,000 in shares of Sprott Uranium Miners ETF (NYSEARCA:URNM) on 10/3/2025.

IQVIA Stock Up 3.7%

IQV traded up $7.98 during trading on Friday, hitting $225.09. The company had a trading volume of 1,446,586 shares, compared to its average volume of 1,627,939. The firm’s 50-day moving average price is $205.80 and its 200 day moving average price is $181.06. The company has a market capitalization of $38.33 billion, a PE ratio of 30.88, a PEG ratio of 2.52 and a beta of 1.34. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $228.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IQV. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. raised their target price on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. BMO Capital Markets began coverage on shares of IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target on the stock. Cowen cut IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Barclays lifted their target price on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $240.61.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IQV. Physician Wealth Advisors Inc. lifted its holdings in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares during the last quarter. Westside Investment Management Inc. boosted its holdings in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in IQVIA in the 3rd quarter valued at about $30,000. Finally, AllSquare Wealth Management LLC bought a new position in IQVIA in the 1st quarter valued at about $33,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by corporate insiders.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.